Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

EpiSwitch™ blood-based test successful in diagnosing and staging breast cancer in Caucasian patient cohort

Oxford BioDynamics
Posted on: 29 Sep 17
  •       EpiSwitch showed high specificity in correctly identifying all four stages of breast cancer in 136 patients
  •       Following completion of this initial milestone, OBD is to further analyse patients with a family history of breast cancer and high risk of genetic predisposition


Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce that, using its proprietary technology platform EpiSwitch™, it has been successful in diagnosing breast cancer in a Caucasian cohort of patients provided by the Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Gliwice Branch, Poland.


As part of the collaboration with MCMCC, OBD has successfully stratified patients representing all four stages of breast cancer against healthy controls using its EpiSwitch™ blood-based test. The EpiSwitch™ markers used showed high specificity and robustness across the cohort of patients and potentially provide an important research insight into epigenetic controls of the disease.


With completion of this first milestone, OBD plans to further expand its analysis across the cohort of 136 patients, focusing on the patients with a family history of breast cancer and high risk of genetic predisposition. OBD aims to develop validated stratifications for the prevalent subtypes of breast cancer, prognosis and predisposition risks, specific for the Caucasian ethnic group.


MCMCC is part of European Society of Medical Oncology and is the primary government oncological research institution in Poland.


Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:


“We are very pleased with the latest results delivered by our EpiSwitch™ technology in which we have been successful in diagnosing and staging breast cancer in a Caucasian patient cohort. We are delighted to be working with MCMCC and extremely grateful for the excellent quality of the clinical cohort provided for our study. We are looking forward to the next stage of our collaboration, as we believe our technology can deliver stratification insights that will assist oncologists and their patients for better, more informed clinical decisions in the difficult cases that involve a family history or high genetic predisposition for breast cancer.


We are excited with the latest developments in this project and the benefits in patient care we would be able to offer, and look forward to providing further updates in due course.”

Editor's Details

Mike Wood

Last updated on: 29/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.